Literature DB >> 3971527

Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.

R L Rothbard, P G Fitzpatrick, C W Francis, D M Caton, W B Hood, V J Marder.   

Abstract

The influence of a systemic lytic state on reperfusion obtained after intracoronary streptokinase (SK) therapy has been evaluated in 15 patients with acute myocardial infarction and complete coronary occlusion. Coronary angiographic studies and measurements of blood fibrinolytic parameters were repeated at 15 min intervals during the infusion of a standard dose of SK and were compared with the results with approximately one-tenth the standard dose. Successful reperfusion was obtained in only 20% (2/10) of patients receiving the low dose, compared with a 75% to 80% success rate in patients receiving the standard dose as initial treatment (4/5) or as follow-up treatment of patients in whom low-dose therapy failed (6/8). There was a striking association between reperfusion and development of the lytic state in that all 12 treatments resulting in reperfusion also caused a lytic state and all seven treatments that failed to produce a lytic state also failed to induce reperfusion (p less than .001). Among the successfully treated patients, the dose of SK that induced a lytic state was relatively constant. However, coronary arterial thrombi differed in susceptibility to treatment. Sensitive thrombi (5/12) dissolved before the lytic state occurred and at a lower SK dose than that needed to cause a lytic state; more resistant thrombi (7/12) required a longer time and a significantly larger SK dose to dissolve. These results indicate that intrinsic properties of the thrombus influence the rate and outcome of treatment and that a minimal dose of SK (about 200,000 U) is required to ensure lasting reperfusion in susceptible patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971527     DOI: 10.1161/01.cir.71.3.562

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

Authors:  J P Monassier; M Hanssen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?

Authors:  W Kasper; T Meinertz; H Just
Journal:  Klin Wochenschr       Date:  1986-04-01

4.  Bleeding complications of intracoronary fibrinolytic therapy in acute myocardial infarction. Assessment of risk in a randomised trial.

Authors:  F W Verheugt; M J van Eenige; J C Res; M L Simoons; P W Serruys; F Vermeer; D C van Hoogenhuyze; P J Remme; C de Zwaan; F Baer
Journal:  Br Heart J       Date:  1985-11

5.  Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.

Authors:  J J Hoffmann; J J Bonnier; J B de Swart; P Custers; M Vijgen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.

Authors:  W Kasper; T Meinertz; H Wollschläger; T Bonzel; C Chen; T Hofmann; A Zeiher; H Drexler; H Just
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.

Authors:  V J Marder; P A Kinsella; M J Brown
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.

Authors:  J Brügemann; J van der Meer; B H Takens; H Hillege; K I Lie
Journal:  Br Heart J       Date:  1990-12

9.  Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.

Authors:  J D Gemmill; K J Hogg; F G Dunn; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1994-09

Review 10.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.